Documents
-
- Download
- Title page_Table of contents
- open access
-
- Download
- Chapter 1 General introduction
- open access
-
- Download
- Chapter 2
- open access
- Full text at publishers site
-
- Download
- Chapter 3
- open access
- Full text at publishers site
-
- Download
- Chapter 4
- open access
- Full text at publishers site
-
- Download
- Chapter 5
- open access
- Full text at publishers site
-
- Download
- Chapter 6
- open access
- Full text at publishers site
-
- Download
- Chapter 7
- open access
- Full text at publishers site
-
- Download
- Chapter 8 Summary and future perspectives
- open access
-
- Download
- Back cover
- open access
-
- Download
- Propositions
- open access
In Collections
This item can be found in the following collections:
Targeting chondrosarcoma and osteosarcoma cell metabolism : the IGF pathway and beyond
Thesis explored potential new therapeutic strategies by identifying cellular pathways that are essential for chondrosarcoma and osteosarcoma cell survival. Although clinical trials with IGF1R inhibitors have disappointing results in osteosarcoma, this thesis strengthens the view that the IGF pathway can be an effective target for osteosarcoma therapy if an appropriate selection of patients is treated with IGF1R/IR dual inhibitors. When optimized clinical trials targeting the IGF pathway will be performed in the future, chondrosarcoma patients should not be recruited, as there is limited preclinical rationale for the efficacy of IGF1R targeting agents in chondrosarcoma. We identified two promising pathways that can be used to target chondrosarcoma; the NAD+ synthesis pathway and glutaminolysis. Our results suggest that chondrosarcoma patients should be included in future studies with drugs that interfere in these pathways,...
Show moreThesis explored potential new therapeutic strategies by identifying cellular pathways that are essential for chondrosarcoma and osteosarcoma cell survival. Although clinical trials with IGF1R inhibitors have disappointing results in osteosarcoma, this thesis strengthens the view that the IGF pathway can be an effective target for osteosarcoma therapy if an appropriate selection of patients is treated with IGF1R/IR dual inhibitors. When optimized clinical trials targeting the IGF pathway will be performed in the future, chondrosarcoma patients should not be recruited, as there is limited preclinical rationale for the efficacy of IGF1R targeting agents in chondrosarcoma. We identified two promising pathways that can be used to target chondrosarcoma; the NAD+ synthesis pathway and glutaminolysis. Our results suggest that chondrosarcoma patients should be included in future studies with drugs that interfere in these pathways, regardless of their IDH1/2 mutation status.
Show less- All authors
- Peterse, E.F.P.
- Supervisor
- Bovée, J.V.M.G.
- Co-supervisor
- Cleton-Jansen, A.M.
- Committee
- Dijkstra, P.D.S.; Wilmink, J.W.; Hassan, A.B.; Hogendoorn, P.C.W.
- Qualification
- Doctor (dr.)
- Awarding Institution
- Medicine / Leiden University Medical Center (LUMC) , Leiden University
- Date
- 2018-06-13
- ISBN (print)
- 9789463323406